Lindsey Garner
Family · Southaven, MSNPI 1255799730
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $14,169 of the $15,958 with a category attached, or 88.8%. It is spread thinly across 37 manufacturers, the largest accounting for just 15.1% — the pattern of someone who eats at a lot of different presentations. Among family clinicians in MS with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 548 payments — averaging $29.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$2K
- Bayer$1K
- Amgen$1K
- Abbott$1K
- AstraZeneca$844
- Johnson & Johnson$790
- plus $9K from 31 others
What the payments were for
- Travel & lodging$1,78911%
- Food & beverage$14,16989%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 15 | $2,412 |
| Bayer | 52 | $1,290 |
| Amgen | 48 | $1,043 |
| Abbott | 26 | $1,020 |
| AstraZeneca | 31 | $844 |
| Johnson & Johnson | 46 | $790 |
| Philips North America LLC | 38 | $777 |
| Novo Nordisk | 16 | $664 |
| Boehringer Ingelheim | 25 | $607 |
| Novartis | 35 | $592 |
| Merck | 28 | $581 |
| Alnylam Pharmaceuticals Inc. | 24 | $576 |
| Esperion Therapeutics, Inc. | 24 | $553 |
| Pfizer | 29 | $528 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 16 | $517 |
| Medtronic | 14 | $483 |
| Irhythm Technologies, Inc. | 11 | $296 |
| Heartflow, Inc. | 4 | $293 |
| Impulse Dynamics (USA) Inc. | 5 | $262 |
| AbbVie | 2 | $191 |
| Inspire Medical Systems, Inc. | 3 | $189 |
| E.r. Squibb & Sons, L.L.C. | 5 | $167 |
| Lilly USA, LLC | 3 | $148 |
| Regeneron Healthcare Solutions, Inc. | 7 | $141 |
| Arbor Pharmaceuticals, Inc. | 9 | $114 |
| Sanofi-aventis U.S. LLC | 6 | $112 |
| Amarin Pharma, Inc. | 5 | $101 |
| Kowa Pharmaceuticals America, Inc. | 4 | $92 |
| Regeneron | 1 | $88 |
| SK Life Science, Inc. | 1 | $83 |
| Urovant Sciences Inc | 1 | $81 |
| Corcept Therapeutics | 1 | $75 |
| Cvrx, Inc. | 4 | $73 |
| Azurity Pharmaceuticals, Inc. | 4 | $72 |
| Daiichi Sankyo Inc. | 2 | $49 |
| Lexicon Pharmaceuticals, Inc. | 2 | $36 |
| Ionis Pharmaceuticals, Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- WATCHMAN FLX$1,896
- Kerendia$322
- WATCHMAN Access System$289
- FFRct$245
- NEXLIZET$241
- NEXLETOL$241
- Repatha$229
- THORATEC HEARTMATE 3 LVAS IMPLANT KIT$226
- MitraClip$153
- OPTIMIZER$145
- CARDIOMEMS$145
- Abre$140
- RYBELSUS$125
- JARDIANCE$125
- Otezla$120
- UBRELVY$119
- FARXIGA$117
- LOKELMA$117
- MOUNJARO$108
- Saxenda$106
How this compares
$15,958 in reported general payments places this provider in the 95th percentile of 3,007 family providers in Mississippi.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XareltoRivaroxaban | 214 | $227,559 |
| EntrestoSacubitril/Valsartan | 118 | $145,568 |
| EliquisApixaban | 74 | $81,746 |
| JardianceEmpagliflozin | 52 | $64,820 |
| Repatha SureclickEvolocumab | 56 | $62,727 |
| FarxigaDapagliflozin Propanediol | 23 | $32,538 |
| VascepaIcosapent Ethyl | 41 | $31,652 |
| BrilintaTicagrelor | 18 | $15,651 |
| EdarbyclorAzilsartan Med/Chlorthalidone | 15 | $8,256 |
| Ezetimibe | 295 | $5,975 |
| Atorvastatin Calcium | 351 | $3,187 |
| Rosuvastatin Calcium | 290 | $3,179 |
| Ranolazine ErRanolazine | 36 | $3,113 |
| Valsartan | 83 | $2,446 |
| Metoprolol Succinate | 164 | $2,287 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonXarelto | $790 | $227,559214 claims |
| NovartisEntresto | $592 | $145,568118 claims |
| PfizerEliquis | $528 | $81,74674 claims |
| Boehringer IngelheimJardiance | $607 | $64,82052 claims |
| AstraZenecaFarxiga, Brilinta | $844 | $48,18841 claims |
| Arbor Pharmaceuticals, Inc.Edarbyclor | $114 | $8,25615 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 3,007 family providers in Mississippi.
Other family in Southaven
- Angela UgwuanyiSouthaven$13K
- Dodie McGeeRaymond$772K
- Gina BurgeJackson$237K
- Christy DavisJackson$208K
- Maranda EversollFlowood$197K
- Dana DelaskiJackson$158K
- Kristin CarrollJackson$158K
- Shannon FryeryOxford$127K
- Nativel CollinsMantachie$73K
- Ashley CocilovaFlowood$72K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.